Press Releases Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
109,000 ^KRW	+0.37%		+5.72%	-6.68%

May. 14	Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daewoong Pharmaceutical : Reports Q1 2024 Financial Results	Apr. 29	PU
Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.	Dec. 11	PU
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin	Dec. 05	PU
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA	Nov. 27	AQ
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030	23-10-25	PU
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market	23-10-19	AQ
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines	23-08-17	PU
Daewoong Pharmaceutical : Reports Second Quarter 2023 Financial Results	23-07-26	PU
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	23-06-13	AQ
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	23-06-13	AQ
Daewoong Pharmaceutical : reaches sales of KRW292.3 billion and business profits of KRW31 billion in the first quarter…	23-05-02	PU
Daewoong Pharmaceutical : announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio	23-04-27	PU
Daewoong pharmaceutical : ‘Envlo’ of Daewoong Pharmaceutical, to be launched in the global markets... Entering the 1.54 billion USD Market in Brazil and Mexico	23-02-24	PU
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea	23-01-25	AQ
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates	23-01-04	AQ
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update	22-08-01	AQ
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative	22-04-12	AQ
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update	22-01-24	AQ
HanAll Biopharma Reports Third Quarter 2021 Results	21-10-28	AQ
Evolus : Strengthens Balance Sheet, Secures $40 Million Investment	20-07-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Press Releases

Filters